PARLIAMENT QUESTION: RESEARCH DEVELOPMENT AND INNOVATION SCHEME

1. At a Glance

• RDI Scheme = ₹1 lakh crore corpus to bridge financing gap for deep-tech, research-driven, private-sector innovation via long-term, low/nil-interest debt & equity [1][2].
• Operates through a two-tier fund structure (Special Purpose Fund → Second-Level Fund Managers) — a novel financing architecture for Indian science funding [3][4].
• Fresh Parliament Q&A (29 Jul 2026) reveals scheme now shows real project sanctions (TDB, BIRAC) — moved from approval-stage to disbursement-stage. UPSC angle: tests Cabinet-to-implementation timeline and institutional linkages (ANRF, TDB, BIRAC).

2. Why in the News

• 29 Jul 2026: Lok/Rajya Sabha question answered disclosing ₹1,000 crore each sanctioned to TDB and BIRAC; TDB approved 22 projects (₹4,744 crore total cost, ₹2,192 crore RDI support); BIRAC shortlisted 8 projects (₹390.35 crore) [1][4].
• Follow-on/related PQs same period on RDI Fund under ANRF and low-interest long-term loans [5][6].

3. Background & Evolution

• 5 Feb 2024: Anusandhan National Research Foundation (ANRF) Act, 2023 (Act 25 of 2023) came into force, giving apex strategic direction to national R&D [3].
• ANRF mandated to mobilise ₹50,000 crore (2023–28) via ANRF Fund, Innovation Fund, Science & Engineering Research Fund, and Special Purpose Funds [3].
• 1 Sep 2025 (Cabinet approval): Cabinet approved RDI Scheme to scale up R&D in "Strategic and Sunrise Domains" [2].
• 3 Nov 2025: RDI Scheme/Fund of ₹1 lakh crore formally launched [3].
• Special Purpose Fund (SPF) created within ANRF as custodian of the ₹1 lakh crore corpus [3].
• BIRAC's first national call — ₹2,000 crore RDI-linked biotech call — announced separately [7].

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• Targets private-sector R&D financing gap — India's private R&D spend is historically low vs GDP; RDI seeks to crowd in private capital via patient/low-cost debt [1][2].
• Growth & risk capital framing signals venture-style de-risking of deep-tech, unlike traditional grant-only science funding [2].

Scientific/Technological

• TRL 4+ threshold targets post-lab, pre-commercial technologies — the classic "valley of death" between research and market [1].
• Sectoral focus: biotech (BIRAC channel), broader Technology Development Board channel — cuts across strategic (defence-adjacent, semiconductors) and sunrise (AI, biotech, clean energy) domains [2][7].

Administrative/Governance

• Two-tier structure (ANRF-SPF → SLFMs → end recipients) adds intermediation layers (AIFs/FROs) — introduces private fund-manager discretion into public R&D financing, a governance novelty worth scrutiny [3][1].
• Implementation split across multiple nodal agencies (TDB, BIRAC) under one umbrella scheme — coordination and monitoring challenge [1][4].

Legal/Constitutional

• Statutory anchor is ANRF Act, 2023 — RDI Scheme itself is executive/Cabinet-approved, not separately legislated [2][3].

6. Recent Developments (last 12-18 months)

• 5 Feb 2024: ANRF Act notified/in force [3].
• 1 Sep 2025: Cabinet approves RDI Scheme [2].
• 3 Nov 2025: RDI Fund (₹1 lakh crore) formally launched [3].
• Late 2025: BIRAC first national call of ₹2,000 crore RDI-linked biotech funding announced [7].
• 29 Jul 2026: Parliament disclosure — ₹1,000 crore each sanctioned to TDB/BIRAC; TDB clears 22 projects, BIRAC shortlists 8 [1][4].

7. Prelims Hooks

• RDI Scheme outlay: ₹1 lakh crore over 6 years [1].
• Custodian of RDI corpus: Special Purpose Fund (SPF) within ANRF, not directly with DST [3].
• ANRF established under ANRF Act, 2023 (Act No. 25 of 2023), in force 5 Feb 2024 [3].
• ANRF's own 5-year (2023–28) fund mobilisation target: ₹50,000 crore — distinct from RDI's ₹1 lakh crore [3].
• RDI eligibility floor: Technology Readiness Level (TRL) 4 and above [1].
• Delivery channel term: Second-Level Fund Managers (SLFMs) = AIFs + Focused Research Organisations (FROs) [1].
• Amount sanctioned each to TDB and BIRAC: ₹1,000 crore (total ₹2,000 crore) [1][4].
• TDB approved projects: 22, total project cost ₹4,744 crore, RDI support ₹2,192 crore [1][4].
• BIRAC shortlisted: 8 projects, worth ₹390.35 crore [1][4].
• Cabinet approved RDI Scheme on 1 September 2025 [2].
• RDI Scheme formally launched 3 November 2025 [3].
• Scheme covers "Strategic and Sunrise Domains" per Cabinet approval title [2].
• Financing instruments: debt and equity, at low/nil interest, long tenor [1][2].
• BIRAC's first national RDI-linked biotech call size: ₹2,000 crore [7].

8. Mains Relevance

• GS-III: Science & Technology — indigenization of technology, developments in application of science & technology; also Indian Economy — investment models, growth capital.
• GS-II (secondary): Government policies/interventions for development in S&T sectors.
• Sample stems: 1. "Discuss how the Research, Development and Innovation (RDI) Scheme seeks to bridge India's deep-tech financing gap. Examine institutional challenges in a multi-tier fund-manager model." (GS-III) 2. "Critically examine the relationship between the Anusandhan National Research Foundation and the RDI Scheme in India's research funding architecture." (GS-II/III) 3. "Private capital, public mandate — assess risks of routing sovereign R&D funds through Alternative Investment Funds and Focused Research Organisations." (GS-III, governance angle)

9. Related Topics to Study Next

• Anusandhan National Research Foundation (ANRF) — parent statutory body governing RDI Fund [3].
• Technology Development Board (TDB) — implementing agency, pre-dates RDI, DSIR-linked.
• BIRAC (Biotechnology Industry Research Assistance Council) — Dept. of Biotechnology PSU channel for biotech deep-tech.
• Deep Tech Fund of Funds — parallel/complementary innovation financing vehicle under discussion in Parliament [from search: PRID=2226469].
• Technology Readiness Level (TRL) framework — DRDO/ISRO-origin classification now central to funding eligibility.
• Alternative Investment Funds (AIF) regulatory framework (SEBI) — governs SLFM structuring.
• National Deep Tech Startup Policy — sectoral overlap with RDI's sunrise-domain focus.

10. Common Errors / Trap Areas

• Confusing RDI Scheme (₹1 lakh crore, Cabinet scheme, 2025) with ANRF's own ₹50,000 crore (2023-28) mobilisation target — these are separate corpora [1][3].
• Assuming RDI Fund is directly administered by DST — actual custodian is the SPF within ANRF, disbursed via SLFMs, not a direct ministry grant [3].
• Mixing up TDB (Technology Development Board, cross-sector) with BIRAC (biotech-specific) — both got ₹1,000 crore each but serve different domains [1][4].
• Assuming RDI Scheme needs separate parliamentary legislation — it is a Cabinet-approved scheme under the existing ANRF Act, 2023 framework, not a new Act [2][3].
• TRL floor is 4, not TRL 1 (basic research) — RDI targets post-proof-of-concept, pre-commercialisation stage only [1].